| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Sep―23 |
Structural Insights into an Aptainhibitor of the SARS-CoV-2 E Protein Using Molecular Docking, Molecular Dynamics, and Biophysical Analyses |
Miyssa Imam Abdelmageed Mohamed, Jin-Pyo Lee, Woo-Ri Shin, Dae-Young Park, In-Hwan Oh, Su-Min Lee, Jiho Min, Ji-Young Ahn, Yang-Hoon Kim |
| 2 |
[GO] |
2026―Sep―15 |
Bridging the Antiviral Gap: A BAC-Based Non-Infectious SARS-CoV-2 Replicon Reveals Potent Antisense Gapmers |
Agnieszka Ruszkowska, Agnieszka Baliga-Gil, Julita Piasecka, Maria Ciechanowska, Ryszard Kierzek, Elzbieta Kierzek |
| 3 |
[GO] |
2026―Jul―28 |
Targeted FcRn to Deliver Epitope-Optimized RBD Confers Broad-Spectrum Mucosal Protection Against SARS-CoV-2 |
Xinlan Chen, Yan Wu, Yanhai Wang, Chenshu Zhao, Lijuan Fang, Xuerui Zhu, Jia Lu, Xiao Gao, Zhongfa Zhang, Haoyu Li, Yingrui Yan, Pengfei Zhou, Xiaoyan Pan |
| 4 |
[GO] |
2026―Mar―25 |
Development of broadly cross-reactive mRNA COVID-19 vaccines based on trimeric RBDs of Spike protein and NSP12 to overcome immune imprinting |
Arianna De Chiara, Caterina Giachino, Maria Franca Pirillo, Andrea Campanile, Emilio Pellino, Alessandra Gallinaro, Guendalina Froechlich, Chiara Falce, Annagiulia Scognamiglio, Simone Totaro, Maria Vittoria Liguori, Rosa Peltrini, Alfonso De Simone, Stefania Capone, Zoppoli Pietro, Donatella Negri, Andrea Cara, Alfredo Nicosia, Emanuele Sasso |
| 5 |
[GO] |
2026―Mar―07 |
Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses |
Zhenghao Yu, Mouraya Hussein, Yuanling Bao, Ana Alcalá Lalinde, Pascal Zion Kroon, Eva Thuiller, Zhi Zhang, Luis Enjuanes, Sonia Zuñiga, Ben Berkhout, Elena Herrera-Carrillo |
| 6 |
[GO] |
2026―Mar―05 |
A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines |
Han Young Seo, Haewon Jung, Se-Young Lee, Hae-Gwang Jung, Hee Cho, Yu-Min Son, Yeonju Bak, Seo-Yeon Hwang, Jung-Hee Kim, In Ho Park, Jeon-Soo Shin, Jong-Won Oh |
| 7 |
[GO] |
2026―Feb―26 |
Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza |
Mai N. Vu, Jessica A. Neil, Charley Mackenzie-Kludas, Andrew Kelly, Hyon-Xhi Tan, Kanta Subbarao, Wen Shi Lee, Adam K. Wheatley |
| 8 |
[GO] |
2025―Dec―09 |
Aptamer-Based Approaches for Sensitive Detection and Epitope Mapping of SARS-CoV-2 Spike Protein |
Suttinee Poolsup, Elnaz Yaghoobi, Aliaksandra Radchanka, Nandanee Mulloo, Spencer Uguccioni, John Paul Pezacki, Abdullah Khraibah, Aasha Jawad, Gurcharan K. Uppal, Yuxuan Gu, Benjamin Patrick Lapointe, Nico Hüttmann, Zoran Minic, Polina V. Artyushenko, Irina A. Shchugoreva, Anastasia V. Rogova, Felix N. Tomilin, Dmitry Morozov, Anna S. Kichkailo, Olga S. Kolovskaya, Maxim V. Berezovski |
| 9 |
[GO] |
2025―Oct―01 |
SARS-CoV-2 infection in hiPSC-derived neurons is cathepsin-dependent and causes differential accumulation of HIF1ɑ and phosphorylated tau |
Kettunen Pinja, Ruuska Janika, Quirin Tania, Ojha Ravi, Saber H. Saber, Julian D.J. Sng, Sean Morrison, Bahaa Al-Mhanawi, Mohammed R. Shaker, Simon De Neck, Anja Kipar, Lassi Paavolainen, Ernst Wolvetang, Merja Joensuu, Koistinaho Jari, Rolova Taisia, Balistreri Giuseppe |
| 10 |
[GO] |
2025―Aug―22 |
Dual inhibition of ACE-2 and TMPRSS2: A promising strategy to mitigate SARS-CoV-2 severity in smokers |
Kingshuk Panda, Srinivasan Chinnapaiyan, Hoshang J. Unwalla |
| 11 |
[GO] |
2025―Aug―14 |
ASOs reduce SARS-CoV-2 viral titers in Syrian golden hamsters |
John J. Rossi |
| 12 |
[GO] |
2025―Jun―21 |
Antisense Oligonucleotides Targeting the SARS-CoV-2 Nucleocapsid Gene Decrease Viral Titers in Hamsters |
Christopher Fitzpatrick, Nicolas Meunier, Sophie Lepoder, Sophie Dhorne-Pollet, Bruno Da Costa, Bernard Klonjkowki, Jean-François Eléouët, Veronica A. Burzio, Bernard Delmas, Eric Barrey |
| 13 |
[GO] |
2025―Jun―02 |
ACE-2 Blockade & TMPRSS2 Inhibition Mitigate SARS-CoV-2 Severity Following Cigarette Smoke Exposure in Airway Epithelial Cells In Vitro |
Shah S. Hussain, Emily Falk Libby, Jacelyn E. Peabody Lever, Jennifer L. Tipper, Scott E. Phillips, Marina Mazur, Qian Li, Javier Campos-Gómez, Kevin S. Harrod, Steven M. Rowe |
| 14 |
[GO] |
2025―May―20 |
Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV |
Kinga Maziec, Agnieszka Baliga-Gil, Elzbieta Kierzek |
| 15 |
[GO] |
2025―May―14 |
Differentially expressed ncRNAs as key regulators in infection of human bronchial epithelial cells by the SARS-CoV-2 Delta variant |
Glory Ranches, Hubert Hackl, Viktoria Zaderer, Melanie Ploner, Wilfried Posch, Doris Wilflingseder, Kai Kummer, Alexander Huettenhofer |
| 16 |
[GO] |
2025―Mar―31 |
Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine research and development |
Chiranjib Chakraborty, Yi-Hao Lo, Manojit Bhattacharya, Arpita Das, Zhi-Hong Wen |
| 17 |
[GO] |
2025―Mar―25 |
mRNA-encoded ACE2 decoy lipid nanoparticles for neutralizing SARS-CoV-2 variants |
Lays Cordeiro Guimarães, Heloísa Athaydes Seabra Ferreira, Pedro Pires Goulart Guimarães |
| 18 |
[GO] |
2025―Mar―20 |
Deciphering the NSP12/7/8 complex: Key insights into coronavirus replication and potential therapeutic targets |
Gao Luwen, Zhou Liyan, Abdul Rahman, Zulqarnain Baloch |
| 19 |
[GO] |
2025―Jan―30 |
COVID-19 mRNA vaccines are effective at stopping a nosy virus |
Uxue Beloki, Laura Salaberry, Carla Ortuño-Moya, Angie Molina, Cristian Smerdou |
| 20 |
[GO] |
2025―Jan―29 |
In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection |
Yuta Suzuki, Takayuki Miyazaki, Yoko Ida, Tatsuya Suzuki, Yumi Itoh, Shuto Nakao, Keita Kondo, Kenji Kubara, Keisuke Nishioka, Hiroki Muto, Ryuji Watari, Toshifumi Hirayama, Dai Kakiuchi, Shinya Sato, Satoshi Inoue, Yoshifumi Uemoto, Yohei Mukai, Atsushi Hoshino, Toru Okamoto, Junji Matsui |
| 21 |
[GO] |
2025―Jan―18 |
Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7 |
Deepa Singh, Tushar Kushwaha, Rajkumar Kulandaisamy, Vikas Kumar, Kamal Baswal, Saras H. Tiwari, Arkadyuti Ghorai, Manoj Kumar, Saroj Kumar, Soumya De, Aparoy Polamarasetty, Deepak Sehgal, Madhumohan R. Katika, Suresh Gadde, Marceline Côté, Sarala R. Kayampeta, Mohan B. Appaiahgari, Krishna K. Inampudi |
| 22 |
[GO] |
2024―Oct―16 |
mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice |
Charlie Fricke, Lorenz Ulrich, Jana Kochmann, Janina Gergen, Kristina Kovacikova, Nicole Roth, Julius Beer, Daniel Schnepf, Thomas C. Mettenleiter, Susanne Rauch, Benjamin Petsch, Donata Hoffmann, Martin Beer, Björn Corleis, Anca Dorhoi |
| 23 |
[GO] |
2024―Sep―10 |
Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA |
Alexandra Sakai, Gagandeep Singh, Mahsa Khoshbakht, Scott Bittner, Christiane V. Löhr, Randy Diaz-Tapia, Prajakta Warang, Kris White, Luke Le Luo, Blanton Tolbert, Mario Blanco, Amy Chow, Mitchell Guttman, Cuiping Li, Yiming Bao, Joses Ho, Sebastian Maurer-Stroh, Arnab Chatterjee, Sumit Chanda, Adolfo García-Sastre, Michael Schotsaert, John R. Teijaro, Hong M. Moulton, David A. Stein |
| 24 |
[GO] |
2024―Aug―23 |
PLA-PEG as an alternative to PEGylated lipids for nanoparticle-based DNA vaccination against SARS-CoV-2 |
Walison Nunes da Silva, Pedro Henrique Dias Moura Prazeres, Pedro Pires Goulart Guimarães |
| 25 |
[GO] |
2024―Aug―15 |
Aptamer Decorated Nanocarriers for Viral Adsorption: a Special Look at COVID-19 |
Somayeh Handali, Mohsen Rezaei |
| 26 |
[GO] |
2024―Aug―15 |
Nanobody against SARS-CoV-2 non-structural protein Nsp9 inhibits viral replication in human airway epithelia |
Tomas Venit, Jeremy Blavier, Sibusiso B. Maseko, Sam Shu, Lilia Espada, Christopher Breunig, Hans-Peter Holthoff, Sabrina C. Desbordes, Martin Lohse, Gennaro Esposito, Jean-Claude Twizere, Piergiorgio Percipalle |
| 27 |
[GO] |
2024―Jun―15 |
Unbiased plasma profiling using pre-selected RNA aptamer pools predicts mortality in COVID-19 and identifies protein risk-factors |
Asger Givskov Jørgensen, Daniel Miotto Dupont, Søren Fjelstrup, Claus Bus, Cecilie Bo Hansen, Thomas Benfield, Peter Garred, Peter M.H. Heegaard, Jørgen Kjems |
| 28 |
[GO] |
2024―May―24 |
A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and viral replication |
Martina Tuttolomondo, Stephanie Thuy Duong Pham, Mikkel Green Terp, Virginia Cendán Castillo, Nazmie Kalisi, Stefan Vogel, Niels Langkjær, Ulla Melchior Hansen, Helge Thisgaard, Henrik Daa Schrøder, Yaseelan Palarasah, Henrik Jørn Ditzel |
| 29 |
[GO] |
2024―Feb―28 |
Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics |
Miron Sopic |
| 30 |
[GO] |
2024―Jan―10 |
MicroRNA-Centered Theranostics for Pulmoprotection in Critical COVID-19 |
Manel Perez-Pons, Marta Molinero, Iván D. Benítez, María C. García-Hidalgo, Shambhabi Chatterjee, Christian Ba¨r, Jessica González, Antoni Torres, Ferran Barbé, David de Gonzalo-Calvo |
| 31 |
[GO] |
2023―Oct―25 |
Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome |
Roberto Giambruno, Elsa Zacco, Camilla Ugolini, Andrea Vandelli, Logan Mulroney, Manfredi D’Onghia, Bianca Giuliani, Elena Criscuolo, Matteo Castelli, Nicola Clementi, Massimo Clementi, Nicasio Mancini, Tiziana Bonaldi, Stefano Gustincich, Tommaso Leonardi, Gian Gaetano Tartaglia, Francesco Nicassio |
| 32 |
[GO] |
2023―Aug―28 |
The current landscape of long COVID clinical trials: NIH’s RECOVER to Stanford Medicine’s STOP-PASC initiative |
Chiranjib Chakraborty, Manojit Bhattacharya |
| 33 |
[GO] |
2023―Jun―28 |
Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus |
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty |
| 34 |
[GO] |
2023―Apr―23 |
Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2 |
Guibin Lin, Huan Yan, Jing Sun, Jincun Zhao, Yuan Zhang |
| 35 |
[GO] |
2023―Apr―06 |
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern? |
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty |
| 36 |
[GO] |
2023―Mar―15 |
Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance? |
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty |
| 37 |
[GO] |
2023―Feb―26 |
IPs-GRUAtt: An Attention Mechanism-Based Bidirectional Gated Recurrent Unit Network for Predicting Phosphorylation Sites of SARS-CoV-2 Infection |
Guiyang Zhang, Qiang Tang, Pengmian Feng, Wei Chen |
| 38 |
[GO] |
2023―Feb―14 |
Discovery of DNA aptamers targeting SARS-CoV-2 nucleocapsid protein and protein binding epitopes for label-free COVID-19 diagnostics |
Suttinee Poolsup, Emil Zaripov, Nico Hüttmann, Zoran Minic, Polina V. Artyushenko, Irina A. Shchugoreva, Felix N. Tomilin, Anna S. Kichkailo, Maxim V. Berezovski |
| 39 |
[GO] |
2023―Feb―13 |
Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants |
Chiranjib Chakraborty, Abinit Saha, Manojit Bhattacharya, Kuldeep Dhama, Govindasamy Agoramoorthy |
| 40 |
[GO] |
2023―Jan―21 |
Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents |
Amy D. Gelinas, Tiong Kit Tan, Sai Liu, Javier G. Jaramillo, James Chadwick, Adam C. Harding, Chi Zhang, Brian E. Ream, Chelsea N. Chase, Matthew R. Otis, Thomas Lee, Daniel J. Schneider, William S. James, Nebojsa Janjic |
| 41 |
[GO] |
2022―Nov―02 |
Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants |
Qidong Hu, Ying Zhao, Namir Shaabani, Xiaoxuan Lyu, Colin Powers, Haotian Sun, Vincent Cruz, Karen Stegman, Jia Xu, Amber Fossier, Yu Huang, Giang Ho, Yi Kao, Zhihao Wang, Zhenping Wang, Yue Hu, Yi Zheng, Lilian Kyaw, Cipriano Zuluaga, Hua Wang, Hong Pei, Robert Allen, Hui Xie, Henry Ji, Runqiang Chen |
| 42 |
[GO] |
2022―Aug―14 |
New Insights on Circular RNAs and Their Potential Applications as Biomarkers, Therapeutic Agents, and Preventive Vaccines in Viral Infections: with a glance at SARS-CoV-2 |
Nasim Rahmani-Kukia, Ardeshir Abbasi |
| 43 |
[GO] |
2022―Jul―13 |
Clinical Significance of Interferon Signaling Based on mRNA-microRNA Integration and Plasma Protein Analyses in Critically Ill COVID-19 Patients |
Yuki Togami, Hisatake Matsumoto, Jumpei Yoshimura, Tsunehiro Matsubara, Takeshi Ebihara, Hiroshi Matsuura, Yumi Mitsuyama, Takashi Kojima, Masakazu Ishikawa, Fuminori Sugihara, Haruhiko Hirata, Daisuke Okuzaki, Hiroshi Ogura |
| 44 |
[GO] |
2022―Jun―25 |
Cytokines and MicroRNAs in SARS-CoV-2: What do we know? |
Fahimeh Zamani Rarani, Bahman Rashidi, Mohammad Hassan Jafari Najaf Abadi, Michael R. Hamblin, Seyed Mohammad Reza Hashemian, Hamed Mirzaei |
| 45 |
[GO] |
2022―Jun―11 |
Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients |
Maria Calderon-Dominguez, Eva Trejo-Gutierrez, Almudena González-Rovira, Lucía Beltrán-Camacho, Marta Rojas-Torres, Sara Eslava-Alcón, Daniel Sanchez-Morillo, Juan Calderon-Dominguez, Mª Pilar Martinez-Nicolás, Estibaliz Gonzalez-Beitia, Mª Dolores Nieto-Martín, Teresa Trujillo-Soto, Manuel A. Rodríguez-Iglesias, Juan A. Moreno, Rafael Moreno-Luna, Mª Carmen Durán-Ruiz |
| 46 |
[GO] |
2022―Mar―16 |
The accessible promoter-mediated supplementary effect of host factors provides new insight into the tropism of SARS-CoV-2 |
Guifang Du, Xiang Xu, Junting Wang, Xuejun Wang, Yang Ding, Fei Li, Yu Sun, Huan Tao, Yawen Luo, Hao Li, Xiaochen Bo, Hebing Chen |
| 47 |
[GO] |
2022―Feb―13 |
RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection |
Samira Marx, Beate M. Kümmerer, Christian Grützner, Hiroki Kato, Martin Schlee, Marcel Renn, Eva Bartok, Gunther Hartmann |
| 48 |
[GO] |
2021―Dec―31 |
SARS-CoV-2 Causes a Significant Stress Response Mediated by Small RNAs in the Blood of COVID-19 Patients |
Xi Liu, Yan-Zi Wen, Zi-Liang Huang, Xia Shen, Jun-Hao Wang, Yi-Hai Luo, Wen-Xin Chen, Zhao-Rong Lun, Hui-Bin Li, Liang-Hu Qu, Hong Shan, Ling-Ling Zheng |
| 49 |
[GO] |
2021―Oct―22 |
Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells |
Rina Hashimoto, Ayaka Sakamoto, Sayaka Deguchi, Renxing Yi, Emi Sano, Akitsu Hotta, Kazutoshi Takahashi, Shinya Yamanaka, Kazuo Takayama |
| 50 |
[GO] |
2021―Sep―01 |
D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin? |
Chiranjib Chakraborty, Abinit Saha, Ashish Ranjan Sharma, Manojit Bhattacharya, Sang-Soo Lee, Govindasamy Agoramoorthy |
| 51 |
[GO] |
2021―Jun―24 |
A novel G-quadruplex aptamer-based spike trimeric antigen test for the detection of SARS-CoV-2 |
Ankit Gupta, Anjali Anand, Neha Jain, Sandeep Goswami, Anbalagan Ananthraj, Sharanabasava Patil, Rahul Singh, Amit Kumar, Tripti Shrivastava, Shinjini Bhatnagar, Guruprasad R. Medigeshi, Tarun Kumar Sharma |
| 52 |
[GO] |
2021―Jan―21 |
Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19 |
Aditya Kiran Gatta, Venkata Rao Josyula |
|
